PE20020052A1 - Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato - Google Patents

Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato

Info

Publication number
PE20020052A1
PE20020052A1 PE2001000451A PE2001000451A PE20020052A1 PE 20020052 A1 PE20020052 A1 PE 20020052A1 PE 2001000451 A PE2001000451 A PE 2001000451A PE 2001000451 A PE2001000451 A PE 2001000451A PE 20020052 A1 PE20020052 A1 PE 20020052A1
Authority
PE
Peru
Prior art keywords
function
sulfonamid
enhance
glutamate receptor
derivatives useful
Prior art date
Application number
PE2001000451A
Other languages
English (en)
Inventor
Thomas John Bleisch
George William Cuff
Paul Leslie Ornstein
Dennis Michael Zimmerman
Macklin Brian Arnold
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20020052A1 publication Critical patent/PE20020052A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO {(2R)-2-[4-(4-{2-[(METILSULFONIL)AMINO]ETIL}FENIL)FENIL]PROPIL}[(METILETIL)SULFONIL]AMINA DE FORMULA I EL CUAL POTENCIA LA FUNCION DE RECEPTORES DE GLUTAMATO Y PUEDE SER UTIL PARA TRATAR LA DEPRESION, ESQUIZOFRENIA
PE2001000451A 2000-05-19 2001-05-18 Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato PE20020052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20600300P 2000-05-19 2000-05-19

Publications (1)

Publication Number Publication Date
PE20020052A1 true PE20020052A1 (es) 2002-02-02

Family

ID=22764580

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000451A PE20020052A1 (es) 2000-05-19 2001-05-18 Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato

Country Status (24)

Country Link
US (1) US20030225163A1 (es)
EP (1) EP1311474A1 (es)
JP (1) JP2003534316A (es)
KR (1) KR20030007644A (es)
CN (1) CN1429205A (es)
AR (1) AR035915A1 (es)
AU (1) AU2001259053A1 (es)
BR (1) BR0110874A (es)
CA (1) CA2409830A1 (es)
CZ (1) CZ20023797A3 (es)
DZ (1) DZ3343A1 (es)
EA (1) EA200201234A1 (es)
EC (1) ECSP014078A (es)
HR (1) HRP20020918A2 (es)
HU (1) HUP0302255A3 (es)
IL (1) IL152156A0 (es)
MX (1) MXPA02010020A (es)
NO (1) NO20025459L (es)
PE (1) PE20020052A1 (es)
PL (1) PL358180A1 (es)
SK (1) SK16312002A3 (es)
SV (1) SV2002000459A (es)
WO (1) WO2001090057A1 (es)
ZA (1) ZA200208749B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6984756B2 (en) 2000-05-19 2006-01-10 Eli Lilly And Company Process for preparing biphenyl compounds
ES2225558T3 (es) 2000-06-13 2005-03-16 Eli Lilly And Company Derivados de sulfonamida.
EP1438036A2 (en) * 2001-10-12 2004-07-21 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
EP2102153A1 (en) * 2006-12-11 2009-09-23 Eli Lilly & Company Ampa receptor potentiators
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006537A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company N-substituted sulfonamide derivatives

Also Published As

Publication number Publication date
NO20025459D0 (no) 2002-11-14
BR0110874A (pt) 2003-02-11
DZ3343A1 (fr) 2001-11-29
IL152156A0 (en) 2003-05-29
NO20025459L (no) 2002-11-14
PL358180A1 (en) 2004-08-09
HRP20020918A2 (en) 2004-02-29
CA2409830A1 (en) 2001-11-29
HUP0302255A3 (en) 2005-11-28
CN1429205A (zh) 2003-07-09
EP1311474A1 (en) 2003-05-21
AU2001259053A1 (en) 2001-12-03
US20030225163A1 (en) 2003-12-04
JP2003534316A (ja) 2003-11-18
KR20030007644A (ko) 2003-01-23
EA200201234A1 (ru) 2003-04-24
MXPA02010020A (es) 2003-02-12
SV2002000459A (es) 2002-07-03
ZA200208749B (en) 2004-01-30
HUP0302255A2 (hu) 2003-11-28
AR035915A1 (es) 2004-07-28
ECSP014078A (es) 2002-02-25
CZ20023797A3 (cs) 2003-04-16
SK16312002A3 (sk) 2003-05-02
WO2001090057A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
EA200702471A1 (ru) Новые гетероциклические соединения в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
ATE402945T1 (de) Neuer steroidagonist für fxr
EA200701122A1 (ru) Потенциаторы рецепторов глутамата
DK1778677T3 (da) Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
ZA201102735B (en) Antagonists of the vanilloid receptor subtype 1(vr1) and uses thereof
DK1685105T3 (da) Allosteriske modulatorer af metabotropiske glutamatreceptorer
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
NO20032253D0 (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato
BRPI0513912A (pt) derivados de amida de ácido cinurênico como antagonistas do receptor nr2b
PE20090629A1 (es) Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7
WO2007070865A3 (en) Piperazine compounds as agonists of trpv4 channel receptors
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
MXPA05008186A (es) Derivados de quinoxalina saturados y su uso como ligandos receptores de glutamato metabotropico.
MA28811B1 (fr) Nouvelles utilisations de derives d'imidazotriazinones substituees par 2-phenyle
HRP20080075T3 (en) Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists
PE20080279A1 (es) DERIVADOS DE PIRAZOL[4,3-d]TIAZOL COMO INHIBIDORES DE LA PROTEINA QUINASA AURORA 1 Y 2
EA200970573A1 (ru) Агенты, усиливающие действие амра-рецепторов
TW200607499A (en) 2-(1H-indolylsulfanyl)-benzyl amine derivatives

Legal Events

Date Code Title Description
FC Refusal